Jennifer Lin has in-depth practice experience in intellectual property, life sciences, and regulatory compliance in the pan-Asia region. She has assisted in intellectual property prosecution, enforcement, and commercialization in China and Hong Kong S.A.R. and has advised on multiple IP-related transactions including M&A, licensing, joint ventures, and other types of deals for clients from various industries such as Corsair, Gaw Capital Partners, Greystar, Henderson, Incyte, Inflexion, Junshi, P&G, Stonepeak, and Sumitomo Dainippon Pharma.
Jennifer has advised leading pharmaceutical and medical device companies on China's regulatory and compliance regimes in a wide range of legal aspects, including clinical trials, market authorization, human genetic resources, and data exportation. In addition, she has assisted clients that have significant business operations and interests in China and Hong Kong in compliance and risk management of cybersecurity, privacy, and data protection. She also has managed domestic trademark portfolios of Fortune 500 companies and prosecuted Hong Kong standard patents for multiple global biotech and pharmaceutical companies.
Jennifer is recommended by The Legal 500 (2025) and is described as "very efficient and client-oriented."
担当案件
- April 3, 2025
PRC AI Regulation Updates - October 7, 2021
Protection of Trademarks and Intellectual Property in China
"I would like to specifically mention Jennifer Lin. She is very efficient and client-oriented."The Legal 500
- The University of Hong Kong (LL.M. in Intellectual Property and Information Technology 2019; Research Assistant, Law & Technology Centre); Guangdong University of Foreign Studies (LL.B. and B.A. in English 2016, with first class honors)
- Hong Kong (Registered Foreign Lawyer, PRC) and California
- The Legal 500 (2025)
- Mandarin, Cantonese, and English